Resultado de búsqueda
Hace 17 horas · Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
29 de may. de 2024 · They were not truly evaluating a 1:1:1 resuscitation as the median transfusion at 6 h for the conventional coagulation assay group had only 8 U pRBC, 5 U plasma, and 1 U platelets. There is also consideration that the results may be too good as patients treated by TEG had nearly one-quarter the mortality at 6 h and one-half at 28 days, questioning risk of other bias.
Hace 17 horas · MIAMI, May 28, 2024 -- Longeveron Inc. , a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today...
Hace 17 horas · At a current market cap of $162 million, this is clearly underappreciated and unrecognized by the market at the present time. For reference, company peer Kiniksa Pharmaceuticals (KNSA) now has a $1.4 billion market cap on expected sales of $360-$380 million for treating recurrent pericarditis, with single to low double-digit market penetration.
Hace 17 horas · This is a list of Ig Nobel Prize winners from 1991 to the present day.. A parody of the Nobel Prizes, the Ig Nobel Prizes are awarded each year in mid-September, around the time the recipients of the genuine Nobel Prizes are announced, for ten achievements that "first make people laugh, and then make them think". Commenting on the 2006 awards, Marc Abrahams, editor of Annals of Improbable ...
Hace 5 horas · GRACE met its primary endpoint of loss of blood pressure control in the randomized withdrawal phase among patients receiving relacorilant as compared to placebo (odds ratio: 0.17; p-value: 0.02). Consistent with its known safety profile, relacorilant was well-tolerated in both phases of GRACE, with no differences in the randomized withdrawal phase between the relacorilant and placebo groups.
